Materna IPS GmbH: Materna IPS deploys Biometric Solution at Tokyo Haneda Airport
2.9.2021 10:00:00 CEST | news aktuell GmbH | Press release

(Tokyo, Japan): Via 1:1 verification the passenger’s scanned government issued ID picture gets matched with the image captured at the kiosk. The result can enroll into the airports Face Express system at the self bag drop making it a unique cooperation of both systems. That way Tokyo Haneda Airport ensures a streamlined passenger processing while improving airport efficiency and security.
By offering passengers to identify themselves at the self-service touchpoint, physical contact with airport staff and therefore the risk of infection will be minimized. Contactless technology has become an important way to maintain the strict security standards during the pandemic.
Last year Materna IPS successfully installed a total of 104 self bag drop kiosks in Terminals 2 and 3 of the airport. These kiosks have now been upgraded by the unique biometric authentication process (Face Express) in cooperation with Collins Aerospace.
Yuya Yamazaki, Technical Project Manager of TIAT, said: “On behalf of TIAT including management level, we would like to express our sincere appreciation to Materna IPS to release this program before Tokyo 2020 Olympic and Paralympic Games, which is one of our goals of this project.”
With implementing this major project at Tokyo International Airport (HANEDA), Materna IPS continues its market entry in Japan and is expanding its international growth.
Upgrading the Haneda SBD installation with the biometric journey does not only significantly increase the airport’s efficiency and security but also lets Materna IPS extend its business activities in the Japanese market and so expand its international growth.
About Materna IPS GmbH
Materna IPS GmbH (Intelligent Passenger Solutions) as one of the most renowned suppliers for airports and airlines around the world, delivers solutions for automated passenger handling at airports. The company’s range of products and services comprises hardware and software implementations as well as service and maintenance. Their international branches in the USA, Canada, India and the United Kingdom enable Materna IPS to support their customers individually and to react quickly and professionally to market requirements. Materna IPS GmbH is a 100% subsidiary of Materna Information & Communications SE with its headquarters in Germany. The Materna Group currently employs more than 2,600 people around the world and generated sales of 355.1 million euros in 2020.
Picture is available at AP Images (http://www.apimages.com)
Contacts
Jana EullHead of MarketingMaterna IPS GmbH
Voßkuhle 37
44141 Dortmund
Images
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
They’re really going for it: emporia launches the first 5G smartphone with a screen warranty15.7.2026 08:40:22 CEST | Press release
Better safe than sorry: the emporiaSMART.8 with Smartcover and rubber protectors
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist29.6.2026 12:28:23 CEST | Press release
The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will commence later this year.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

